OpportunityTitle: Synthesis and Preclinical Evaluation of Medications to Treat Substance Use Disorders (SUDs) (R01)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.  Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Description: The National Institute on Drug Abuse (NIDA) is soliciting grant (R01) applications to support the synthesis and preclinical evaluation of new molecular entities as potential treatments for Substance Use Disorders (SUDs). Responsive applications may include synthesis, identification, optimization and preclinical efficacy and/or safety assessment of lead compounds. Applications must provide timelines and decision-trees with go/no-go criteria to advance or discontinue testing a compound. Possible new molecular entities include, but are not limited to, small molecules, enzymes, antibodies, and vaccines. The goal is to identify candidate compounds and advance them towards Investigational New Drug (IND) submission.
GrantorContactEmailDescription: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
GrantorContactText: NIH OER Webmaster&lt;br/&gt;FBOWebmaster@OD.NIH.GOV&lt;br/&gt;